EGFR and non-small cell lung carcinoma: Moreover, recent studies have indicated that some oncogenic miRNAs contribute to the resistance of EGFR mutated NSCLC tumors to TK inhibitors.[26, 27] Therefore, a miRNA‐based combination therapeutic strategy is promising and beneficial for improving therapeutic response.